WuXi Biologics Announced Global Strategic Partnership with Pharmadule Morimatsu at its Singapore CRDMO Center Project
Singapore, June 26, 2023 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced a strategic partnership with Pharmadule Morimatsu, a diversified multinational company with core technology and rich project experience in core equipment, process systems, digital intelligence pharmaceutical plant solutions. Under the partnership, Pharmadule Morimatsu will provide modular facilities for the WuXi Biologics Singapore CRDMO Center project.
This strategic cooperation starts with the integrated modular plants for two important production facilities in the WuXi Biologics Singapore CRDMO Center, and will include design, manufacturing, factory acceptance testing (FAT), installation, commissioning, and validation. The Singapore CRDMO Center will adopt a new generation of modular fabrication with the majority of construction work taking place in Morimatsu’s workshop, where it will be built, assembled and FAT-tested. This allows the quality, schedule, cost, and risk associated with the project to be well managed and controlled; compared with conventional construction, this method also greatly shortens the project cycle.
Chris Chen, CEO of WuXi Biologics, commented, “Singapore is one of the most advanced pharmaceutical hubs in the world, as well as a critical part of our global biomanufacturing network. By leveraging Pharmadule Morimatsu’s expertise and experience, we are confident that our Singapore CRDMO Center will contribute to our track record in establishing global sites successfully as demonstrated by our greenfield site in Ireland, further enabling global partners with premier quality services and solutions.”
Mr. Weihua Tang, CEO of Morimatsu LifeSciences, commented, “WuXi Biologics is an important partner of our company, we are very delighted to cooperate with them once again. In this cooperation, Pharmadule Morimatsu will utilize a new generation of modular fabrication methods to assist WuXi Biologics in expanding production capacity, accelerating the empowerment of global pharmaceutical companies, reducing R&D costs, and benefiting patients worldwide.”
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2022, WuXi Biologics is supporting 588 integrated client projects, including 17 in commercial manufacturing.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
About Morimatsu LifeSciences
Morimatsu LifeSciences is a subsidiary of Morimatsu International Holdings Limited (Morimatsu International, stock code: 2155.HK), covering pharmaceutical, biopharmaceutic, FMCG, cosmetics, electronic chemicals and other industries, provides clients with “core equipment/Machinery + Value added + digitalized intelligence overall Plant Solutions” (” MVP Solutions “), mainly including Shanghai Morimatsu Pharmaceutical Equipment Engineering Co., LTD., Morimatsu (Suzhou) Life LifeSciences Co., LTD., Shanghai Morimatsu Biotechnology Co., LTD., and Pharmadule Morimatsu AB., Morimatsu Pharmadule (Singapore) Private Limited as well as their subsidiaries. Morimatsu LifeSciences is focusing on the research and development, manufacturing, and sales of products in related fields.